Treace Medical Concepts, Inc. (TMCI)

NASDAQ: TMCI · Real-Time Price · USD

4.410

-0.080 (-1.78%)

Sep 21, 2026, 2:42 PM EDT - Market open

Market Cap	286.80M -35.5%
Revenue (ttm)	205.31M -4.0%
Net Income	-59.52M
EPS	-0.93
Shares Out	65.03M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	237,689
Open	4.540
Previous Close	4.490
Day's Range	4.380 - 4.540
52-Week Range	1.170 - 7.095
Beta	1.41
Analysts	Hold
Price Target	5.50 (+24.72%)
Earnings Date	Nov 5, 2026

About TMCI

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percupla... [Read more]

Industry Medical Devices

Sector Healthcare

IPO Date Apr 23, 2021

Employees 450

Stock Exchange NASDAQ

Ticker Symbol TMCI

Website https://www.treace.com

Full Company Profile

Financial Performance

In 2025, Treace Medical Concepts's revenue was $212.69 million, an increase of 1.59% compared to the previous year's $209.36 million. Losses were -$59.00 million, 5.85% more than in 2024.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for TMCI stock is "Hold." The 12-month stock price target is $5.5, which is an increase of 24.72% from the latest price.

Price Target

$5.5

(24.72% upside)

Analyst Consensus: Hold

Stock Forecasts

News

Treace Medical presents results from three clinical studies at AOFAS meeting

Treace Medical (TMCI) announced the presentation of the results from three clinical studies at the American Orthopaedic Foot & Ankle Society, or AOFAS, annual meeting in Seattle, Washington. The prese...

3 days ago - TheFly

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

PONTE VEDRA, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgic...

3 days ago - GlobeNewsWire

Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting

New product offerings extend bunion market leadership and accelerate penetration into new foot & ankle market adjacencies New product offerings extend bunion market leadership and accelerate penetrati...

5 days ago - GlobeNewsWire

Treace Medical Concepts Earnings Call Transcript: Q2 2026

Revenue declined 4% year-over-year in Q2 2026 to $45.4M, but case volume growth accelerated to high single digits, driven by new product adoption and market share gains. Full-year guidance was raised, with expectations for sequential revenue growth and a strong Q4.

6 weeks ago - Transcripts

Treace Medical Concepts Earnings release: Q2 2026

Treace Medical Concepts released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.

6 weeks ago - Filings

Treace Medical Concepts Quarterly report: Q2 2026

Treace Medical Concepts has published its Q2 2026 quarterly earnings report on August 7, 2026.

6 weeks ago - Filings

Treace Medical Concepts Reports Second Quarter 2026 Financial Results

PONTE VEDRA, Fla., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...

6 weeks ago - GlobeNewsWire

Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...

1 month ago - PRNewsWire

Treace to Report Second Quarter 2026 Financial Results on August 7, 2026

PONTE VEDRA, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...

1 month ago - GlobeNewsWire

Treace Medical price target raised to $4 from $2 at Truist

Truist raised the firm’s price target on Treace Medical (TMCI) to $4 from $2 and keeps a Hold rating on the shares as part of a broader research note previewing…

2 months ago - TheFly

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Treace Medical Concepts, Inc. (TMCI)

SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI) against...

2 months ago - GlobeNewsWire

Treace Medical Concepts Transcript: Sidoti Small-Cap Virtual Investor Conference

Strong market share gains and a broadened product portfolio have driven accelerated procedure volumes and doubled market penetration to 8% in 2025. Financial performance improved with significant reductions in EBITDA loss and cash usage, while new minimally invasive technologies and expanded sales efforts position the company for continued growth.

3 months ago - Transcripts

Treace Medical announces first surgical case with HyperPlate XM implant

Treace Medical (TMCI) Concepts announced the successful completion of the first case utilizing its HyperPlate XM Dynamic Compression Locking Implant. “The launch of HyperPlate XM implants marks anothe...

3 months ago - TheFly

Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System

New portfolio addition to drive further penetration into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base Ne...

3 months ago - GlobeNewsWire

Treace to Present at the Sidoti Small Cap Conference

PONTE VEDRA, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...

3 months ago - GlobeNewsWire

Treace Medical Concepts Transcript: AGM 2026

The meeting covered director elections, executive compensation, and auditor ratification, all of which passed. A 4.7% average salary increase for non-executives was disclosed during the Q&A. Final voting results will be filed with the SEC.

4 months ago - Transcripts

Treace Medical Concepts, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Treace Medical Concepts, Inc. (NASDAQ: TMCI). The investigation focuses on ...

4 months ago - GlobeNewsWire

Treace Medical Concepts Earnings Call Transcript: Q1 2026

Q1 2026 saw a 10% revenue decline due to lower-priced product mix, but case volumes grew mid-single digits and gross margins remained strong. New product adoption is accelerating, with guidance reaffirmed for improved performance and revenue growth in Q4 2026.